Cutiss
Z├╝rich
About Cutiss
Cutiss AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin is expected to result in a minimally scarring outcome after transplantation. denovoSkin received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $94.6M
- Funding stage: Late Stage Venture
- Last round: Series C (Sep 2025)
- Website: cutiss.swiss
- Phone: +41 43-549-21-10
Industries & Categories
Beauty, Biotechnology, Cosmetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/cutiss-98739 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.